Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Mexico Health Reporter.
Press releases published on October 3, 2025
Contemporary Care Introduces TMS Therapy to Naples, Florida
Image by Contemporary Care NAPLES, Fla., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Contemporary Care today announced the availability of Transcranial Magnetic Stimulation therapy at its Naples, Florida facility, expanding access to advanced psychiatric treatment …
Publication relating to transparency notifications
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 3, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA ( …
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of …
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization, and rational therapeutic …
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
ROCKAWAY, N.J., Oct. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Jennifer Hayes will be joining electroCore, effective October 6, 2025, …
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the …
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on October 2, 2025, the compensation …
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2025, it …
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an …
Smith+Nephew announce latest scientific data supporting new ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing for pressure injury prevention
Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is pleased to announce exciting new data from Professor Amit Gefen and his research group published in the International Wound Journal,1 demonstrating the pressure injury prevention …
Mesa Laboratories, Inc. to Announce Second Quarter Results on November 6, 2025
LAKEWOOD, Colo., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the second quarter of fiscal year 2026 following market close on Thursday, November 6, 2025. About Mesa …
Frontier Medicines Announces Publication in Structure Highlighting Novel E3 Ligase DCAF2 can be Harnessed for Targeted Protein Degradation
- First report of high-resolution structures of DCAF2 - - Frontier™ Platform key to discovering covalent ligands to selectively target DCAF2 - BOSTON and SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a …
National Performance Group Recognizes 16 Intermountain Health Hospitals for High Quality Patient Care Delivery
SALT LAKE CITY, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Sixteen Intermountain Health hospitals have received Vizient’s 2025 Bernard A. Birnbaum, MD, Quality Leadership Awards for demonstrating excellence in high-quality clinical and patient care. Three …
Visa Lighting® Expands Cove-Inspired Harmony Line with 11 New Models
Glendale, WI, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Visa Lighting, a leader in architectural lighting for over 60 years and still proudly manufacturing all of its luminaires in the USA, has expanded its popular Harmony recessed ceiling fixture family with …
Sienna Announces Third Quarter 2025 Results Release Date and Conference Call
MARKHAM, Ontario, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) announced that it will report its 2025 third quarter results after market close on Thursday, November 13, 2025. Nitin Jain, President and …
Marking Eczema Awareness Month – Clinical Research Validates Strata Skin Sciences’ XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis
HORSHAM, Pa., Oct. 03, 2025 (GLOBE NEWSWIRE) -- In recognition of Eczema Awareness Month, STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative …
Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
BOSTON and LONDON, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced its abstract has been accepted for oral presentation at …